α2-Antiplasmin Conversion to Plasmin Substrate via Monoclonal Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for improving tissue healing, modifying angiogenesis, and treating thrombotic diseases such as heart attacks and ischemic stroke are limited by the regulatory effects of α2-antiplasmin on plasmin activity, necessitating the development of compositions and methods to increase plasmin activity and modulate fibrinolysis.
Innovation Solution
Administering therapeutic agents that bind to α2-antiplasmin at specific binding sites to convert it from an inhibitor to a plasmin substrate, thereby increasing plasmin activity, using monoclonal antibodies or other molecules that target the serpin domain or amino-terminus of α2-antiplasmin, and facilitating fibrin degradation or preventing platelet formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If α2-antiplasmin is present to regulate plasmin activity, then fibrinolysis is controlled, but plasmin activity is insufficient to effectively treat thrombotic diseases
Solution Approach 1:
The patent converts the harmful inhibitory effect of α2-antiplasmin on plasmin into a beneficial effect by using monoclonal antibodies to bind α2-antiplasmin, thereby converting it from a plasmin inhibitor into a plasmin substrate. This allows the body's natural regulatory protein to become part of the therapeutic mechanism rather than remaining an obstacle
Solution Approach 2:
Monoclonal antibodies serve as intermediaries that bind to α2-antiplasmin and facilitate its conversion from inhibitor to substrate. The antibodies mediate the interaction between the regulatory protein and plasmin, enabling the desired functional shift without directly modifying α2-antiplasmin's structure
2Productivity
If plasmin activity is increased to dissolve thrombi, then thrombotic diseases are treated, but uncontrolled fibrinolysis may cause bleeding complications
Solution Approach 1:
The patent creates a feedback-controlled system where monoclonal antibodies bind to α2-antiplasmin in a regulated manner, allowing plasmin activity to be enhanced when needed (thrombus dissolution) while maintaining natural regulatory mechanisms to prevent excessive fibrinolysis. The antibody-α2-antiplasmin complex provides controlled substrate availability rather than unregulated plasmin activation
3Productivity
If conventional thrombolytic therapy is used, then fibrin clots are dissolved, but the regulatory effects of α2-antiplasmin limit therapeutic efficacy
Solution Approach 1:
The patent changes the functional parameter of α2-antiplasmin from inhibitor to substrate through monoclonal antibody binding. This parameter change fundamentally alters the kinetic relationships in the fibrinolysis system, converting a rate-limiting inhibitory step into a rate-enhancing substrate conversion step, thereby increasing overall thrombus dissolution rate while preserving regulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances fibrinolysis and modulates angiogenesis, effectively treating conditions like myocardial infarction, thrombosis, and ischemic stroke by increasing plasmin activity and shifting the serpin-protease reaction from the inhibitory to the substrate pathway, thereby amplifying fibrinolysis and promoting tissue healing.
Implementation Method 1
administering therapeutic agents that bind to α2-antiplasmin at specific binding sites to convert it from an inhibitor to a plasmin substrate
Implementation Method 2
shifting the serpin-protease reaction from the inhibitory to the substrate pathway, thereby amplifying fibrinolysis
Implementation Method 3
Plasmin is known to have a central role in degrading fibrin, the protein component of blood clots
Implementation Method 4
Enzymatic dissolution of these thrombi (fibrinolysis) by plasmin, a serine protease, reduces death and disability
Data Source
AI summary
Methods for increasing plasmin activity in a patient in need thereof are provided, comprising administering to the patient a therapeutic amount of an agent which binds to α2-antiplasmin at a binding site to increase conversion of α2-antiplasmin from an inhibitor to a plasmin substrate, thereby increasing plasmin activity in the patient. Also provided are methods for the identification of compounds or molecules that increase plasmin activity, comprising determining whether the compound or molecule binds to a binding site on α2-antiplasmin which increases the conversion of α2-antiplasmin from an inhibitor to a plasmin substrate, wherein the compound or molecule is not an antibody, thereby identifying a compound or molecule which increases plasmin activity. Further provided are pharmaceutical compositions and methods of use thereof for the treatment of myocardial infarction, thrombosis, ischemic stroke, and pulmonary embolism.